Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00920816
First received: June 11, 2009
Last updated: July 9, 2014
Last verified: July 2014
  Purpose

The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.


Condition Intervention Phase
Kidney Neoplasms
Drug: Axitinib (AG-013736)
Drug: Sorafenib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Progression Free Survival (PFS): First-Line Participants [ Time Frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107) ] [ Designated as safety issue: No ]
    Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease [PD]), or from adverse event (AE) data (where outcome was "Death"). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is >= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.

  • Progression Free Survival (PFS): Second-Line Participants [ Time Frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103) ] [ Designated as safety issue: No ]
    Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease [PD]), or from adverse event (AE) data (where outcome was "Death"). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is >= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.


Secondary Outcome Measures:
  • Percentage of Participants With Objective Response (OR): First-Line Participants [ Time Frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107) ] [ Designated as safety issue: No ]
    Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.

  • Percentage of Participants With Objective Response (OR): Second-Line Participants [ Time Frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103) ] [ Designated as safety issue: No ]
    Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.

  • Duration of Response (DR): First-Line Participants [ Time Frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107) ] [ Designated as safety issue: No ]
    Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

  • Duration of Response (DR): Second-Line Participants [ Time Frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103) ] [ Designated as safety issue: No ]
    Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

  • Overall Survival (OS): First-Line Participants [ Time Frame: Baseline until death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107) ] [ Designated as safety issue: No ]
    Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

  • Overall Survival (OS): Second-Line Participants [ Time Frame: Baseline until death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103) ] [ Designated as safety issue: No ]
    Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).


Other Outcome Measures:
  • Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): First-Line Participants [ Time Frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose) ] [ Designated as safety issue: No ]
    FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).

  • Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): Second-Line Participants [ Time Frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose) ] [ Designated as safety issue: No ]
    FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).

  • Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): First-Line Participants [ Time Frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose) ] [ Designated as safety issue: No ]
    FKSI-DRS: subset of FKSI which is FACT-Kidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).

  • Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): Second-Line Participants [ Time Frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose) ] [ Designated as safety issue: No ]
    FKSI-DRS: subset of FKSI which is FACT-Kidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).

  • Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: First-Line Participants [ Time Frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose) ] [ Designated as safety issue: No ]
    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

  • Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: Second-Line Participants [ Time Frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose) ] [ Designated as safety issue: No ]
    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

  • Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): First-Line Participants [ Time Frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose) ] [ Designated as safety issue: No ]
    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.

  • Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): Second-Line Participants [ Time Frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose) ] [ Designated as safety issue: No ]
    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.


Enrollment: 492
Study Start Date: August 2009
Estimated Study Completion Date: July 2014
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: Axitinib (AG-013736)
axitinib will be given at a starting dose of 5 mg BID with continuous dosing
Active Comparator: B Drug: Sorafenib
sorafenib will be given at a dose of 400 mg BID continuous dosing

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically documented metastatic renal cell cancer with a component of clear cell histology.
  • Evidence of measurable disease.
  • Patients with mRCC must have received no prior systemic first-line therapy or must have progressive disease per RECIST (version 1.0) after one prior systemic first line regimen for metastatic disease containing sunitinib, cytokine(s), or both.

Exclusion Criteria:

  • Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy.
  • Major surgery less that 4 weeks or radiation less than 2 weeks of starting study drug.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00920816

  Hide Study Locations
Locations
United States, Florida
Pfizer Investigational Site
Miami, Florida, United States, 33176
Pfizer Investigational Site
Miami, Florida, United States, 33143
United States, Illinois
Pfizer Investigational Site
Arlington Heights, Illinois, United States, 60005
Pfizer Investigational Site
Niles, Illinois, United States, 60714
Pfizer Investigational Site
Winfield, Illinois, United States, 60190
United States, Indiana
Pfizer Investigational Site
Carmel, Indiana, United States, 46032
Pfizer Investigational Site
Fishers, Indiana, United States, 46037
Pfizer Investigational Site
Greenfield, Indiana, United States, 46140
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46227
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46219
United States, Missouri
Pfizer Investigational Site
Columbia, Missouri, United States, 65201
United States, Nebraska
Pfizer Investigational Site
Omaha, Nebraska, United States, 68114
United States, Nevada
Pfizer Investigational Site
Henderson, Nevada, United States, 89052
Pfizer Investigational Site
Henderson, Nevada, United States, 89074
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89128
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89148
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89169
United States, New Jersey
Pfizer Investigational Site
Morristown, New Jersey, United States, 07962
Pfizer Investigational Site
Parsippany, New Jersey, United States, 07054
United States, New York
Pfizer Investigational Site
Albany, New York, United States, 12208
Pfizer Investigational Site
Albany, New York, United States, 12206
Pfizer Investigational Site
Latham, New York, United States, 12110
Pfizer Investigational Site
Rexford, New York, United States, 12148
Pfizer Investigational Site
Troy, New York, United States, 12180
United States, North Carolina
Pfizer Investigational Site
Cary, North Carolina, United States, 27518
Pfizer Investigational Site
Raleigh, North Carolina, United States, 27607
Pfizer Investigational Site
Raleigh, North Carolina, United States, 27614
United States, Oregon
Pfizer Investigational Site
Portland, Oregon, United States, 97225
Pfizer Investigational Site
Portland, Oregon, United States, 97227
Pfizer Investigational Site
Portland, Oregon, United States, 97213
Pfizer Investigational Site
Tualatin, Oregon, United States, 97062
United States, Pennsylvania
Pfizer Investigational Site
Hershey, Pennsylvania, United States, 17033-0850
United States, South Carolina
Pfizer Investigational Site
Charleston, South Carolina, United States, 29425
United States, Texas
Pfizer Investigational Site
Amarillo, Texas, United States, 79106
Pfizer Investigational Site
Beaumont, Texas, United States, 77702-1449
Pfizer Investigational Site
Dallas, Texas, United States, 75246
Pfizer Investigational Site
Fort Worth, Texas, United States, 76104
Pfizer Investigational Site
Fort Worth, Texas, United States, 76177
Pfizer Investigational Site
Fort Worth, Texas, United States, 76132
Pfizer Investigational Site
Kerrville, Texas, United States, 78028
Pfizer Investigational Site
McAllen, Texas, United States, 78503
Pfizer Investigational Site
Midland, Texas, United States, 79701
Pfizer Investigational Site
San Antonio, Texas, United States, 78217
Pfizer Investigational Site
San Antonio, Texas, United States, 78258-3912
Pfizer Investigational Site
Webster, Texas, United States, 77598-4420
Pfizer Investigational Site
Weslaco, Texas, United States, 78596
United States, Virginia
Pfizer Investigational Site
Christiansburg, Virginia, United States, 24073
Pfizer Investigational Site
Low Moor, Virginia, United States, 24457
Pfizer Investigational Site
Roanoke, Virginia, United States, 24014
Pfizer Investigational Site
Salem, Virginia, United States, 24153
Pfizer Investigational Site
Wytheville, Virginia, United States, 24382
United States, Washington
Pfizer Investigational Site
Vancouver, Washington, United States, 98684
Pfizer Investigational Site
Vancouver, Washington, United States, 98686
Pfizer Investigational Site
Wenatchee, Washington, United States, 98801
Bosnia and Herzegovina
Pfizer Investigational Site
Banja Luka, Bosnia and Herzegovina, 78000
Pfizer Investigational Site
Sarajevo, Bosnia and Herzegovina, 71000
Pfizer Investigational Site
Tuzla, Bosnia and Herzegovina, 75000
Bulgaria
Pfizer Investigational Site
Sofia, Bulgaria, 1756
Pfizer Investigational Site
Varna, Bulgaria, 9000
Chile
Pfizer Investigational Site
Temuco, Cautin, Chile, 4810469
Pfizer Investigational Site
Providencia, Santiago, RM, Chile, 7501088
Pfizer Investigational Site
Santiago, RM, Chile, 7500710
China, Fujian
Pfizer Investigational Site
FuZhou, Fujian, China, 350025
China, Guangdong
Pfizer Investigational Site
Guangzhou, Guangdong, China, 510060
China, Jiangsu
Pfizer Investigational Site
Nanjing, Jiangsu, China, 210029
Pfizer Investigational Site
Nanjing, Jiangsu, China, 210002
China, Jilin
Pfizer Investigational Site
Changchun, Jilin, China, 130012
China, Shanghai
Pfizer Investigational Site
Shanghai, Shanghai, China, 200127
China, Sichuan
Pfizer Investigational Site
Chengdu, Sichuan, China, 610041
China, Zhejiang
Pfizer Investigational Site
Hangzhou, Zhejiang, China, 310016
China
Pfizer Investigational Site
Beijing, China, 100021
Pfizer Investigational Site
Beijing, China, 100036
Pfizer Investigational Site
Beijing, China, 100853
Pfizer Investigational Site
Beijing, China, 100034
Pfizer Investigational Site
Chongqing, China, 400038
Pfizer Investigational Site
Guangzhou, China, 510515
Pfizer Investigational Site
Nanjing, China, 210009
Pfizer Investigational Site
Shanghai, China, 200032
Pfizer Investigational Site
Shen Yang, China, 110001
Pfizer Investigational Site
Tianjin, China, 300060
Pfizer Investigational Site
Tianjin, China, 300211
Pfizer Investigational Site
Xi'an, China, 710032
India
Pfizer Investigational Site
Hyderabad, Andhra Pradesh, India, 500024
Pfizer Investigational Site
Bangalore, Karnataka, India, 560070
Pfizer Investigational Site
Bangalore, Karnataka, India, 560038
Pfizer Investigational Site
Bangalore, Karnataka, India, 560068
Pfizer Investigational Site
Nagpur, Maharashtra, India, 440012
Pfizer Investigational Site
Nashik, Maharashtra, India, 422 005
Pfizer Investigational Site
Nasik, Maharashtra, India, 422004
Pfizer Investigational Site
Pune, Maharashtra, India, 411 004
Malaysia
Pfizer Investigational Site
Kuala Lumpur, Malaysia, 59100
Mexico
Pfizer Investigational Site
Mexico, DF, Mexico, 14000
Pfizer Investigational Site
Mexico City, Distrito Federal, Mexico, 06726
Pfizer Investigational Site
Toluca, Estado de Mexico, Mexico, 50080
Pfizer Investigational Site
Aguascalientes, Mexico, 20000
Pfizer Investigational Site
Oaxaca, Mexico, 68000
Philippines
Pfizer Investigational Site
Quezon City, Diliman, Philippines
Pfizer Investigational Site
Makati City, Philippines, 1200
Pfizer Investigational Site
Manila, Philippines, 1000
Pfizer Investigational Site
Quezon City, Philippines
Pfizer Investigational Site
Quezon City, Philippines, 1102
Romania
Pfizer Investigational Site
Timisoara, Jud. Timis, Romania, 300239
Pfizer Investigational Site
Cluj-Napoca, Romania, 400015
Russian Federation
Pfizer Investigational Site
Moscow, Russian Federation, 111033
Pfizer Investigational Site
Moscow, Russian Federation, 125284
Pfizer Investigational Site
Moscow, Russian Federation, 105005
Pfizer Investigational Site
Ryazan, Russian Federation, 390026
Pfizer Investigational Site
Ryazan, Russian Federation, 390011
Pfizer Investigational Site
Saint-Petersburg, Russian Federation, 197022
Pfizer Investigational Site
Ufa, Russian Federation, 450054
South Africa
Pfizer Investigational Site
Port Elizabeth, South Africa, 6045
Taiwan
Pfizer Investigational Site
Taichung, Taiwan, 407
Pfizer Investigational Site
Taipei, Taiwan, 112
Ukraine
Pfizer Investigational Site
Dnipropetrovsk, Ukraine, 49005
Pfizer Investigational Site
Kharkiv, Ukraine, 61037
Pfizer Investigational Site
Kyiv, Ukraine, 03115
Pfizer Investigational Site
Kyiv, Ukraine, 04053
Pfizer Investigational Site
Lviv, Ukraine, 79031
Pfizer Investigational Site
Zaporizhzhya, Ukraine, 69040
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided by Pfizer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00920816     History of Changes
Other Study ID Numbers: A4061051
Study First Received: June 11, 2009
Results First Received: July 26, 2013
Last Updated: July 9, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Axitinib in First & Second Line Treatment of Patients With Metastatic Renal Cell Cancer

Additional relevant MeSH terms:
Neoplasms
Carcinoma, Renal Cell
Kidney Neoplasms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Sorafenib
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 22, 2014